AMGN Amgen Inc.

+2  (+1%)
Previous Close 185.5
Open 185.89
Price To Book 9.56
Market Cap 119478608250
Shares 637,219,244
Volume 2,754,246
Short Ratio
Av. Daily Volume 3,308,085

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due 2020.
Tezepelumab - NAVIGATOR
Approval announced May 21, 2018.
Prolia (denosumab)
Glucocorticoid-induced osteoporosis (GIOP)
sNDA approval announced June 11, 2018.
Relapsed Multiple Myeloma
sBLA approval announced June 29, 2017.
Vectibix (Panitumumab)
Wild-Type RAS Metastatic Colorectal Cancer
Approved September 14, 2017.
MVASITM (bevacizumab-awwb)
Biosimilar candidate to Avastin (bevacizumab)
Approved April 15, 2015.
Chronic Heart Failure
Approval announced May 17, 2018.
Phase 3 ongoing. Expected completion 2024.
CNP 520
Alzheimer’s Disease
Approval announced December 1, 2017.
Cardiovascular disease
sBLA approval announced January 5, 2017.
Multiple Myeloma
FDA approval announced October 1, 2018.
Multiple Myeloma
sNDA approved January 17, 2018.
Relapsed Multiple Myeloma
PDUFA date under priority review August 14, 2017. Approval announced July 11, 2017.
Phase 3 Non-Hodgkin’s lymphoma expected 2019.
ABP 798
RITUXAN biosimilar - non-Hodgkin lymphoma
CRL issued June 1, 2018.
ABP 980
Herceptin biosimilar
BLA filing announced December 17, 2018.
ABP 710
REMICADE biosimilar - rheumatoid arthritis
Approved February 7, 2017.
Secondary hyperparathyroidism (SHPT)
CRL issued July 16, 2017. BLA filing resubmission announced July 13, 2018. Advisory committee meeting January 16, 2019 voted 18-1 in favor of approval.
EVENITY (Romosozumab)
Phase 3 interim analysis due 1H 2019.
Omecamtiv mecarbil GALACTIC-HF
Acute heart failure
Phase 2 data estimated 1Q 2019
AMG 301
Second Phase 3 trial initiation announced February 21, 2019.
Omecamtiv mecarbil METEORIC-HF
Acute heart failure
Phase 1 data at ASH December 2018 noted 7/42 CRs
AMG 420
Relapsed. Refractory (R/R) Multiple Myeloma (MM)
Phase 1 data at ASH December 1, 2018 noted 12.5% ORR.
AMG 330
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
FDA approval announced December 14, 2018.
Nplate (Romiplostim)
Immune Thrombocytopenia (Pediatric)
sNDA filing announced December 19, 2018.
Nplate (Romiplostim)
Immune thrombocytopenia (ITP)
Phase 3 data due 2019.
Multiple Myeloma
Phase 1 trial initiation announced February 20, 2019.
AMG 594
Healthy volunteers

Latest News

  1. Amgen Starts Phase III Enrollment for Heart Failure Drug
  2. The Top 5 Biotech Stocks Are Facing Growth Challenges — Are Any Immune?
  3. Cytokinetics Inc (CYTK) Q4 2018 Earnings Conference Call Transcript
  4. The Zacks Analyst Blog Highlights: Walmart, Amgen, Honda, TransCanada and TransUnion
  5. Merck Gets Priority Review for Keytruda in Third-Line SCLC
  6. Amgen, Cytokinetics and Servier Announce Start of METEORIC-HF, the Second Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure
  7. Amgen, Cytokinetics And Servier Announce Start Of METEORIC-HF, The Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure
  8. Top Analyst Reports for Walmart, Amgen and Honda
  9. AbbVie's RA Candidate Upadacitinib Gets FDA Priority Review
  10. Merck's Keytruda Fails to Meet Endpoint in Liver Cancer Study
  11. Roche's (RHHBY) BLA for Lymphoma Drug Gets Priority Review
  12. What Are Teva Pharmaceutical’s Key Growth Drivers in 2019?
  13. Merck Gets Priority Review for Keytruda Combo in Kidney Cancer
  14. Behind the Cutting Edge Technology: The History of Amgen
  15. Is Amgen a Buy?
  16. Amgen Inc. -- Moody's announces completion of a periodic review of ratings of Amgen Inc.
  17. This Is One Company That Could Break Up Bristol-Celgene Deal
  18. [$$] WSJ Tax Guide 2019: The Drug Industry
  19. Despite M&A Spree, Biotech ETFs Slide on Mixed Earnings
  20. Teva (TEVA) Q4 Earnings Miss,'19 View Weak, Shares Down